CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Qurient Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Qurient Co Ltd
801, C Dong, 242, Pangyo-ro, Bundang-gu
Phone: +82 3180601600p:+82 3180601600 SEONGNAM, 13487  South Korea Ticker: 115180115180
Business Summary
Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director Gi YeonNam 44 1/1/2015 1/1/2015
Vice President, Director Jung SikHwang 44 1/1/2015 1/1/2015
Internal Auditor Yun SuKang 46
Director Jae SeungKim 47
Non-Executive Independent Director Jae GwangAhn 46

General Information
Number of Employees: 22 (As of 12/31/2019)
Outstanding Shares: 27,250,001 (As of 4/1/2024)
Shareholders: 16,316
Stock Exchange: KDQ
Fax Number: +82 3180601649


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024